MARKET TALK: GSK May See Relief Rally On Avandia News >GSK.LN
15th Jul 2010 07:32
0632 GMT [Dow Jones] A modest rally in GlaxoSmithKline's (GSK.LN) shares could follow after the FDA voted in favor of keeping Avandia on the US market, says Citigroup. The brokerage notes the withdrawal of Avandia could have reduced the group's '11 EPS by 3.3%, or 6.4% in the event of worldwide with
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
15th Jul 2010 07:32
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0632 GMT [Dow Jones] A modest rally in GlaxoSmithKline's (GSK.LN) shares could follow after the FDA voted in favor of keeping
Read moreUK SMALLCAP ROUNDUP: NXT's Cash Flow Pressured By Sales Fall
14th Jul 2010 12:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps NXT PLC (NXT.LN), U.K. technology and licensing company, Wednesday said fiscal 2010 revenue is "significantly down" on last year, in spite of an improvem
Read morePRESS RELEASE: First nasal vaccine approved in Canada to prevent seasonal influenza
14th Jul 2010 12:05
Health Canada approval of FluMist(R) offers Canadians a safe,(1) more effective (2a,3a) option to protect against the flu MISSISSAUGA, ON, July 14 /CNW/ - AstraZeneca Canada Inc. announced today that Health Canada has approved FluMist(R) (Influenza Vaccine, Live, Attenuated) for the prevention
Read moreMARKET TALK: Citigroup Raises AstraZeneca Price Target
14th Jul 2010 09:41
0841 GMT [Dow Jones] Citigroup raises AstraZeneca (AZN.LN) price target to 3300p from 2800p. Says a look at Brilinta data ahead of the upcoming FDA advisory committee review leads the brokerage to take a more positive view on the outcome than previously. Thinks a recommendation for approval is more
Read moreUK MARKET TALK ROUNDUP: SHARES LOSING
14th Jul 2010 09:41
Stocks on the fall in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 0841 GMT [Dow Jones] Citigroup raises AstraZeneca (AZN.LN) price target to 3300p from 2800p. Says a look at Brilinta data
Read moreUK SMALLCAP ROUNDUP: ASOS Revenue Boosted By Overseas Sales
14th Jul 2010 09:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps ASOS PLC (ASC.LN), an online fashion retailer, Wednesday posted a 48% jump in first-quarter group revenue, helped by a more than doubling of overseas sal
Read moreSilence Therapeutics, AstraZeneca Extend Research Deal
14th Jul 2010 07:32
LONDON (Dow Jones)--Biotechnology company Silence Therapeutics PLC (SLN.LN) said Wednesday it extended a research deal with AstraZeneca PLC (AZN.LN) by another year. Silence specializes in RNA interference, an experimental branch of drug research which involves shutting off or silencing genes in
Read more2nd UPDATE: Calif Supreme Court Reinstates Suit Vs Drug Cos
13th Jul 2010 22:19
(Adds comment from Pfizer in the last paragraph.) By Peter Loftus Of DOW JONES NEWSWIRES The California Supreme Court has reinstated a lawsuit in which retail pharmacies accused Pfizer Inc. (PFE), AstraZeneca PLC (AZN, AZN.LN) and other major drug makers of conspiring to set prices at ar
Read moreUPDATE: Calif. Supreme Court Clears Price-Fixing Suit Vs. Drug Makers
13th Jul 2010 17:54
(Adds details from court ruling beginning in fifth paragraph; comments for attorneys from both sides and company comments beginning in seventh paragraph) By Peter Loftus Of DOW JONES NEWSWIRES The California Supreme Court has reinstated a lawsuit in which retail pharmacies accused Pfizer
Read moreUPDATE: Investor Says Value Of Investments Up In 2Q
13th Jul 2010 08:37
(Adds detail, comment.) By Erik Durhan Of DOW JONES NEWSWIRES STOCKHOLM (Dow Jones)--Investor AB (INVE-B.SK), the investment vehicle of the Swedish Wallenberg family, Tuesday said the value of its investments rose 3.7% in the three months to June 30, driven mainly by growth in its core
Read moreIndia AstraZeneca Set INR576.10 A Share Floor Price For Delisting
6th Jul 2010 14:06
MUMBAI (Dow Jones)--AstraZeneca Pharma India Ltd. (506820.BY) said Tuesday its founder AstraZeneca Pharmaceuticals AB has set a floor price of INR576.10 a share to buyout a 10% free float and delist the company. The Swedish parent has also set a tentative maximum price of INR1,152.00 a share.
Read moreAstraZeneca Teams Up With MRC Technology In Drug Search
5th Jul 2010 09:44
LONDON (Dow Jones)--U.K. drug maker AstraZeneca PLC (AZN.LN) said Monday it teamed up with the commercial arm of the U.K.'s Medical Research Council to scour a library of about 150,000 compounds for possible drug applications. AstraZeneca said the collaboration will search for compounds that sho
Read moreMARKET TALK: Novartis Near Fair Value: Strong Franc Weighs
5th Jul 2010 07:48
0648 GMT [Dow Jones] Novartis (NVS) is close to being fairly valued but the sharp decline in EUR/CHF will start to hit the pharmaceutical company with its heavy Swiss cost base, says Kepler. "Although we are negative on the stock, the fundamentals are starting to give some support and unlike AstraZe
Read moreUK MARKET TALK ROUNDUP: BROKERS COMMENTS
2nd Jul 2010 13:54
Broker comments in the UK today. Compiled by Dow Jones Newswires Markets Desk, [email protected] Contact us in London. +44-20-7842-9464 [email protected] 1254 GMT [Dow Jones] Societe Generale lifts AstraZeneca (AZN.LN) price target to 3150p from 2850p after the company's Crestor
Read more